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THE CHARACTERIZATION OF IgG ANTIBODIES TO GalNAc 
BETA-TERMINATED GLYCANS OF GASTRIC CANCER SURVIVORS
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The elevated anti-GalNAcβ IgG level of serum was shown to be associated with the significantly better survival of patients with gas-
trointestinal cancer. Aim: To characterize the specificity of IgG antibodies to GalNAcβ-terminated glycans of long-term gastric 
cancer survivors. Methods: Serum antibodies and affinity-isolated antibodies were analysed by the indirect and competitive ELISA 
using glycan-polyacrylamide (PAA) conjugates as well as by isoelectric focusing and Western blotting. Results: In the serum probes, 
a partial cross-reactivity of antibodies to GalNAcβ, GalNAcβ1–3Galβ (X2di), GalNAcβ1–3GalNAcβ (PFdi) and GlcNAcβ was ob-
served. The isolated anti-GalNAcβ IgGs demonstrated the cross-reactivity to the X2di glycan mainly. The affinity of the X2di-PAA 
to anti-GalNAcβ IgGs was 11–21 times lower than that of the GalNAcβ-PAA. Anti-X2di and anti-PFdi IgGs demonstrated monore-
activity to their key glycans-PAA used in isolation. The IC50 values of key glycoconjugates ranged from 1 to 5 · 10–7 M. No polyreac-
tivity of antibodies to the unrelated antigens (ferritin, casein and DNA) was found. The polyclonal or oligoclonal distribution of IgG 
bands was established and the monoreactivity of antibodies was not associated with the clonal distribution of bands. Conclusion: 
The cross-reactivity of anti-GalNAcβ antibodies to X2di and related glycans deserves attention in the clarification of the role of anti-
bodies in cancer progression and enhancement of the prognostic potential in the combined determination of antibody markers.
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Many anti-glycan antibodies in humans are 
constantly stimulated by enteric microorganisms 
of the alimentary tract. In different pathologies, inclu-
ding cancer, mucosal barrier dysfunction occurs that 
frequently causes the altered bacterial colonization 
and translocation [1, 2]. This may change the pattern 
and level of circulating anti-glycan antibodies and 
predispose to an adaptive IgG immune response. 
We observed a high serum level of IgG antibodies 
to glycans, including tumor-associated carbohydrate 
antigens, as well as the respective changes in patients 
with gastrointestinal cancer during follow-up [3–5]. 
The determination of the level of some circulating 
anti-glycan antibodies in cancer patients was found 
to be of diagnostic and prognostic significance [3, 
6–9]. The study of the antibody specificity  recognizing 
immunogens may be of clinical value but is complex 
because of the antibody heterogeneity and the di-
versity of natural immunogens. Synthetic antigens 
like polyacrylamide (PAA) glycoconjugates may help 
to solve this problem. The PAA-glycoconjugates are 
homogenous antigens with a single reiterative glyco-
tope [10], enabling a precise detection and isolation 
of glycotope-specific antibodies. Using appropri-
ate glycoconjugates and their optimal combination 
in the determination of antibodies level could improve 
diagnostic and prognostic parameters. The speci ficity 
of affinity-isolated anti-glycan antibodies from the se-
rum of patients with cancer was investigated using 
a set of PAA-glycoconjugates [11–13]. Earlier we had 
found two populations of IgG antibodies reactive 
to GalNAcβ and GalNAcβ1–3GalNAcβ glycans (the lat-
ter is the terminal disaccharide of the para-Forssman 
glycolipid, PFdi) [11]. The elevated serum level of anti-
GalNAcβ IgG was associated with the significantly 
better survival of patients with gastrointestinal cancer 
while the anti-PFdi IgG level was higher in the serum 
of cancer patients than in donors [4, 8].
The aim of the present study was to characterize 
the specificity of serum IgG antibodies to terminated 
GalNAcβ glycans in long-term gastric cancer survivors 
having a high level of antibodies.
MATERIALS AND METHODS
Patients. The study was carried out in accordance 
with the ICH GCP Standards and approved by Tallinn 
Medical Research Ethics Committee. The informed 
consent was obtained from patients under study. 
The diagnosis of patients with gastric cancer (n = 78) 
was verified by the pTNM system [14]. Patients who 
received blood or plasma transfusion or chemo- and 
X-ray therapy were excluded from the study. Long-term 
survivors were selected for isolation and characteriza-
tion of antibodies (Table 1).
Table 1. The characterization of gastric cancer patients
Code Diagnosis Age, sex
Blood 
group
Antibody 
sample
Postoperative 
survival in months
UA Stage II, pT3N0M0G1 63, m A 1 154
PK Stage II, pT3N0M0G2 46, f O 2 135
GV Stage I, pT1N0M0G2–3 72, f A 3 159
JL Stage III, pT4N0M0G2 74, f A 4 82
SK Stage II, pT3N0M0G3 41, f B 5 162
GL Stage III, pT3N1M0G2–3 67, f O 6 140
Glycoconjugates. The synthetic glycoconju-
gates and affinity sorbents were obtained from Lec-
tinity, Russia. The soluble glycoconjugates with the 
N-substituted poly[N-(2-hydroxyethyl)acrylamide] 
(the ethanolamide-type conjugate, 30 kDa, a glycan 
density of 10–20%mol) were designated as glycan-
PAA. The following glycan-PAA conjugates were used: 
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GalNAcβ; X2di (the terminal disaccharide of the X2 glyco-
lipid), GalNAcβ1–3Galβ; PFdi (the terminal disaccharide 
of the para-Forssman glycolipid), GalNAcβ1–3GalNAcβ; 
GlcNAcβ; Tn, GalNAc; TF, Galβ1–3GalNAcα; Тββ (TF), 
Galβ1–3GalNAcβ; GA2 (asialo-GM2), GalNAcβ1–
4Galβ1–4Glcβ; Lac-di-NAc, GalNAcβ1–4GlcNAcβ; Fsdi 
(the terminal disaccharide of the Forssman glycolipid), 
GalNAcα1–3GalNAcβ; Adi (A-disaccharide), GalNAc1–
3Galβ; Bdi (αGal disaccharide), Galα1–3Galβ. 20% 
Tris-PAA (Tris(hydroxymethyl)aminomethane-PAA) was 
used as a negative control.
Indirect and competitive ELISA. Assays were 
performed as described earlier [12]. In the indirect 
ELISA, the level of antibodies was assessed as a ra-
tio of Atest/Acontrol, where Atest is the absorbance with 
the glycan-PAA and Acontrol, with the Tris-PAA. To evalu-
ate the cross-reactivity of serum antibodies, an ex-
cess of soluble glycans-PAA (200 μg/ml) was used 
in the competitive immunoassay. The competitive 
ELISA of isolated antibodies was performed at diffe-
rent concentrations of glycans-PAA. Briefly, one 
of the glycoconjugates was adsorbed onto plates, 
the other or the same glycoconjugate was mixed 
with the serum or purified antibodies in the buffer. 
The mixture was applied to the wells with adsorbed 
glycoconjugates after incubation. The sera or anti-
bodies incubated with the buffer at an appropriate 
dilution were used as control. The inhibition of IgG 
binding to the adsorbed ligand by the soluble ligand 
was evaluated in percentages of subtracted A-values. 
The goat anti-human IgG-phosphatase conjugate was 
used as secondary antibodies. The concentration 
of IgG in antibody samples was determined by ELISA 
as well [12].
Purification of human IgG antibodies. Anti-
bodies were purified as described in reference [12]. 
Briefly, serum probes with a high level of antibodies 
were applied to the glycan-PAA-Sepharose FF. The elu-
tion of antibodies was performed at 4–8 C by using 
8 M urea in the buffer. The product was dialyzed and 
concentrated by ultrafiltration. The admixture of IgM 
or IgA was separated from the affinity-purified IgG an-
tibodies by immunoadsorbtion on the goat-antihuman 
IgM or IgA-agarose. The term “the key glycan-PAA” de-
signates the ligand used in affinity chromatography for 
the isolation of the corresponding antibodies. In some 
cases, the reactivity of isolated antibodies to the key 
glycan-PAA recovered gradually after  storing the solu-
tion for one month at 4 C. A little of precipitate may 
be formed, which should be removed by centrifugation.
Isoelectric focusing and Western blotting. IEF 
was performed in a 1% agarose IEF (GE Healthcare 
Bio-Sciences AB, Sweden) containing 10% gly cerol. 
A pH gradient was formed in the gel with 5% Ampholytes 
high resolution 3–10 (Sigma-Aldrich) or in the gel with 
4% Ampholites and 1% Pharmalyte 5–8 (GE Healthcare 
Bio-Sciences AB, Sweden). The antibody samples 
were focused in the electric field of 10–50 V/cm during 
8 h at 3 C. After focusing, the fractions were trans-
ferred for 1 h to the nitrocellulose sheet (pore size 
0.45 m, Trans-blot, Bio-Rad, Hercules, CA, capil-
lary transfer under pressure). The sheet was kept 
in TBS overnight at 4 C and then blocked in TBS/0.1% 
Tween-20/0.5% BSA/0.1% normal goat serum (NGS) for 
2 h at 20 C. The sheet was washed once with TBS/0.05% 
Tween-20 and incu bated with the goat anti-human 
IgG-alkaline phosphatase conjugate in TBS/0.05% 
Tween-20/0.1% BSA/0.1% NGS for 1.5 h at 20 C. After 
that, the sheet was washed and incubated at 20 C with 
the solution of a 5-bromo-4-chloro-indolylphosphate 
disodium salt (0.2 mg/ml) and nitroblue tetrazolium 
(0.4 mg/ml) (Sigma). After the development of a colour 
reaction, the sheet was washed with TBS and distilled 
water and dried.
Statistical analysis. A Sigma Plot (version 10) 
and Curve Expert (version 1.34) were used. The linear 
regression analysis was conducted by using a Stat-
graphics Plus 5.0.
RESULTS AND DISCUSSION
The cross-reactivity of IgG antibodies to gly-
cans-PAA in serum probes. A partial cross-reactivity 
of serum antibodies to GalNAcβ, X2di, PFdi and GlcNAcβ 
was observed while the cross-reactivity to other related 
glycoconjugates was lower or insignificant (Fig. 1). 
Serum antibodies were cross-reactive to the glycocon-
jugates with an external GalNAcβ residue but not to Тββ 
having an internal GalNAcβ. The cross-reactivity of an-
tibodies to terminal GalNAcβ1–4 linked glycans (GA2, 
Lac-di-NAc) as well as to the glycans with the terminal 
GalNAcα anomer (Tn, Fsdi) was lower or insignificant.
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Fig. 1. The cross-reactivity of serum IgG antibodies to structu rally 
related ligands as established in the competitive  ELISA. The li-
gands-inhibitors are shown under the horizontal zero axis. 
The ligands adsorbed onto the plates are written in the figure. 
The interval designates the extreme values of inhibition for 
the four sera used. The reactivity of antibodies was calculated 
as (Atest minus Acontrol). Atest is the absorbance with PAA glycocon-
jugate; Acontrol is the absorbance with Tris-PAA
The correlation between the levels of some serum 
antibodies was observed that may be due to their partial 
cross-reactivity to the corresponding glycans (Table 2). 
Table 2. The correlation between the levels of serum IgG antibodies 
to structurally related glycans by indirect ELISA
Antibodies r P n
GalNAcβ vs GA2 0.38 0.034 41
GalNAcβ vs X2di 0.36 0.075 37
GalNAcβ vs PFdi 0.41 0.006 52
GalNAcβ vs GlcNAcβ 0.33 0.14 34
X2di vs PFdi 0.33 0.102 37
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When both the glycans inhibit the antibody  binding 
to each other, their mutual cross-reactivity could con-
tribute to better correlation between the antibodies 
levels. Correlation was usually weaker when one-sided 
cross-reactive and non-cross-reactive antibodies were 
presented in serum probes [12, 13].
The reactivity of isolated anti-GalNAcβ IgG 
(samples 1 and 2). The antibodies of sample 1 were 
isolated on the column with a GalNAc-PAA-Sepharose 
(2.8 ml). The serum probes (12 ml) with the level of anti-
GalNAc IgG in the range of 4.2–9.9 (dilution 1:25) were 
applied. Sample 2 was isolated from the serum probe 
of another patient with the level of antibodies of 2.6. 
In serum probes, the reactivity of IgG antibodies to Tn, 
X2di, PFdi, GlcNAcβ and GA2 as well as their partial 
cross-reactivity to these ligands was demonstrated (see 
Fig. 1). The column depleted IgG reactivity to GalNAc-
PAA in sera totally. The isolated IgG antibodies showed 
the cross-reactivity to X2di-PAA (Tables 3, 4; Fig. 2, 3). 
The anti-GalNAcβ IgG isolated from pooled serum pro-
bes obtained from six patients was also cross-reactive 
to X2di-PAA and, similarly to samples 1 and 2 (Table 3), 
bound faintly or not at all other related glycoconjugates 
(not shown). The antibody samples demonstrated close 
values of IC50 for key glycans. The affinity of X2di to an-
tibodies was 11–21 times lower than that of GalNAc 
(Table 4). The inhibition of antibodies of both samples 
by PFdi-PAA (200 g/ml) was in the range of 14–18%. 
The reactivity of anti-GalNAcβ IgG samples to Tn 
(GalNAcα) did not exceed 5%. The human monoclonal 
antibody (6D4), which recognized the GalNAc ligand 
but did not bind Tn, has been described by other authors 
[15]. As found earlier, Tn-monoreactive antibodies were 
isolated on GalNAcα-PAA sorbent from the heteroge-
neous mixture of serum probes obtained from eight 
patients [11]. The results are indicative of the sufficient 
selectivity of GalNAc-PAA-sorbents for isolation of IgG 
antibodies.
Table 3. The reactivity of isolated IgG antibodies to PAA glycoconjugates 
(Atest minus Acontrol in%, indirect ELISA)
Conjugate Sample and key glycan-PAA*1, GalNAcβ 2, GalNAcβ 3, X2di 4, X2di 5, PFdi 6, PFdi
GalNAcβ 100 100 10 2 2 0
X2di 48 24 100 100 4 0
PFdi 1 10 6 3 100 100
GlcNAcβ 0 7 2 0 0 0
Tn 0 5 0 0 0 0
TF 0 0 0 0 0 0
Тββ 0 0 0 1 9 2
GA2 5 3 6 1 0 1
Lac-di-NAc 1 0 0 0 0 0
Fsdi 0 0 0 0 0 0
Adi 0 0 0 0 0 0
Bdi 0 0 0 0 0 0
Note: *The key glycans-PAA is a ligand used for the isolation of antibo-
dies. The reactivity of antibodies to the key glycan-PAA was taken as 100%.
Table 4. The IC50 values (M) of glycans-PAA to the isolated antibodies
Sample, 
antibodies
Conditions
GalNAcβ GalNAcβ X2di X2di PFdi
GalNAcβ X2di GalNAcβ X2di PFdi
1, GalNAcβ 0.30 6.39 0.121
2, GalNAcβ 0.24 2.62 NT
3, X2di 0.30
4, X2di 0.49
5, PFdi 0.34
6, PFdi 0.14
Note: The conditions of the assay: the glycan above is an adsorbed (so-
lid phase) glycan-PAA and the below one is an inhibitor. NT — not tested.
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Fig. 2. a: Sample 1. The inhibition of the binding of purified 
anti-GalNAc IgG to the adsorbed GalNAc-PAA conjugate 
by the soluble GalNAc-PAA ( ) and the soluble X2di-PAA ( ). 
The inhibition of the binding of anti-GalNAc IgG to the adsorbed 
X2di-PAA by the soluble GalNAc-PAA ( ). b: Sample 2. The inhibi-
tion of the binding of purified anti-GalNAc IgG to the adsorbed 
GalNAc-PAA conjugate by the soluble GalNAc-PAA ( ) and 
the  soluble X2di-PAA ( )
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Fig. 3. Sample 3 and sample 4. The inhibition of the binding of pu-
rified anti-X2di IgG to the adsorbed X2di-PAA by the soluble X2di-
PAA. Sample 5 and sample 6.The inhibition of the binding of purified 
anti-PFdi IgG to the adsorbed PFdi-PAA by the soluble PFdi-PAA
The reactivity of isolated anti-X2di IgG (samples 
3 and 4). The antibodies of sample 3 were isolated 
on the column with a X2di-PAA-Sepharose (2.1 ml). 
The serum probes (7 ml) with the level of anti-X2di IgG 
in the range of 5.9–14.9 (dilution 1:25) were applied. 
In the same way, sample 4 was isolated from the serum 
probe of another patient with the level of antibodies 
of 2.4. In one case, probes with a low IgG reactivity 
to the GalNAcβ and GA2 glycans and a high reactivity 
to PFdi were used. In the other case, the serum with 
a high IgG reactivity to GalNAcβ, GA2 and PFdi was 
employed. The column depleted the serum anti-X2di 
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IgG incompletely in the first case but completely 
in the se cond case. In both cases the purified antibo-
dies showed a high reactivity to X2di-PAA. The reactivity 
of antibodies to related glycans was low or absent (Ta-
ble 3). In the competitive assay, related glycans-PAA 
at a concentration of 200 μg/ml inhibited antibodies 
in the range of 2–13%. The antibody samples demon-
strated close IC50-values of X2di-PAA (Table 4; Fig. 4).
A B C D E F G H I
Fig. 4. Isoelectric focusing in a 1% agarose and Western blotting 
of antibody samples. A–G — focusing in the gel with Ampholytes 
3–10. A — anti-GalNAc IgG (sample 1). B, C — monoreactive 
anti-PFdi IgG (samples 5 and 6, respectively). D, E — monore-
active anti-X2di IgG (samples 4 and 3, respectively). F — mono-
reactive anti-Tn IgG [11], G — monoreactive anti-Adi IgG [12]. 
H, I — focusing in the gel with Ampholites 3–10/ Pharmalyte 
5–8. H — Human IgG (total, Sigma). I — anti-X2di IgG (sample 3)
The reactivity of isolated anti-PFdi IgG (sam-
ples 5 and 6). The antibodies of sample 5 were 
isolated on the column with a PFdi-PAA-Sepharose 
(2.8 ml). The serum probe (6 ml) with the level of anti-
PFdi IgG in the range of 6.8–14.3 (dilution 1:25) were 
applied. Sample 6 was isolated from the serum probe 
with the antibody level equal to 11.2. The IgG reactivity 
to GalNAcβ was observed in the serum of the first patient 
(sample 5) but the reactivity of antibodies to X2di and 
Тββ was insignificant. The serum of the second patient 
(sample 6) showed the IgG reactivity to X2di but not 
to GalNAcβ and Тββ. The column depleted the serum 
anti-PFdi IgG totally in both cases. In both cases, the pu-
rified anti-PFdi IgG was specific to PFdi-PAA. Only a slight 
binding to Тββ (9%) was observed for sample 5 (Table 3). 
In the competitive assay Тββ-PAA  (200  μg/ ml) did not 
inhibit antibody binding to PFdi-PAA. The IC50-value 
of PFdi-PAA to the antibodies of sample 6 was lower 
than that of sample 5 (Table 4; Fig. 4).
The isolated IgG antibodies did not bind ferritin and 
casein, and only weakly bound DNA (E. coli, plasmid) 
that are antigens used for the determination of anti-
body polyreactivity. The optimal concentration of IgG 
used in ELISA had similar values (0.02–0.03 g/ml).
The results of study of the specificity of isolated 
antibodies obtained in the present paper and earlier 
may be summarized as follows:
• Antibodies recognized well  and α anomers 
of external GalNAc. Anti-GalNAc IgG did not bind 
GalNAcα-PAA and vice versa, the earlier isolated 
anti-GalNAcα IgG did not bind GalNAc-PAA [11]. 
Anti-X2di IgG did not bind Adi-PAA and vice ver-
sa [12]. Anti-PFdi IgG did not bind Fsdi-PAA.
• Antibodies recognized the external GalNAc 
and Gal residues. The anti-PFdi IgG bound 
weakly or did not bind T (TF)-PAA (indirect 
or competitive ELISA, respectively) and vice versa, 
 TF-reactive antibodies bound weakly or did not 
bind PFdi-PAA [13].
• Antibodies distinguished GalNAc()-terminated 
disaccharides from monosaccharides. Anti-X2di 
and anti-PFdi IgG bound weakly or did not bind 
GalNAc-PAA. Similarly, anti-Adi IgG bound weakly 
GalNAc-PAA [12].
• Anti-GalNAc IgG recognized the GalNAc residue 
in X2di but bound weakly or did not bind PFdi and Тββ 
in PAA-conjugates.
• Anti-GalNAc IgG did not bind or bound weakly 
GlcNAc.
• Anti-GalNAc  and anti-X2di IgG recognized 
 GalNAc1–3Gal linked glycans but bound 
weakly or did not bind GA2 and Lac-di-NAc having 
the  GalNAc1–4 linkage.
• Anti-GalNAc IgG and anti-GalNAc IgG differed 
in reactivity: the former bound the X2di (GalNAc1–
3Gal), whereas the latter did not bind Adi (GalNA-
c1–3Gal) [12].
Noteworthy is that the reactivity and specificity 
of pair samples were similar (Tables 3, 4), despite some 
differences in the reactivity between the pairs of serum 
probes taken for isolation. This may point to some 
selectivity of GalNAc-terminated conjugates and 
affinity sorbents. On the other hand, heterogeneous 
populations of IgG antibodies that differ in specifi-
city to di- and trisaccharides with external GalNAc 
or Gal are present in the serum of different blood 
groups, and were isolated using only GalNAc1–
3Gal-PAA-Sepharose for all probes [12]. The limited 
number of observations was due to that the number 
of long-term survivors having a high level of serum 
antibodies was low. In donors, the level of antibodies 
to GalNAc-terminated glycans was lower. The anti-
GalNAc IgG isolated from the serum of four subjects 
with the elevated level of antibodies demonstrated 
a similar cross-reactivity to X2di. These findings are 
in agreement with those of the study on anti-glycan 
immunoglobulins in donors, which demonstrated eit-
her polyspecificity or narrow epitope specificity [16].
Earlier we characterized anti-TF/TFβ cross-reactive 
IgG populations in long-term cancer survivors and found 
a significantly better survival of gastrointestinal cancer 
patients with an increased serum level of antibodies 
[9, 13]. The elevated serum level of anti-GalNAc IgGs 
cross-reactive to X2di was associated with the significantly 
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better survival of patients with gastrointestinal cancer 
as well [8]. Cross-reactive antibodies deserve attention 
in the clarification of their function in cancer progression.
Analysis of antibodies by IEF. The isolated 
IgG samples were analysed by IEF and the Western 
blotting. IgG samples showed either the oligoclo-
nal or polyclonal distribution of bands (Fig. 4). The 
monoreactivity of antibodies was not associated with 
the clonal distribution of bands. The antibody response 
in humans to many common pathogens is oligoclonal, 
with restricted  usage of Ig V-genes [17]. Bacterial 
polysaccharides with a repeated carbohydrate unit 
have relatively few determinants and complementary 
combinations. Therefore, despite the diversity of anti-
glycan antibodies, the oligoclonal pattern of affinity-
isolated anti-glycan IgG was expected.
Putative natural immunogens. The immunopatho-
logical role of antibodies remains poorly understood 
unless the immunogen or relevant autoantigen is known. 
Enteric microbiota in human is most likely immunogens 
for antibodies. GalNAc is one of the exclusive ligands 
of the C-type lectin of human macrophages, which is in-
volved in the uptake and presentation of glycosylated 
antigens [18, 19]. The GalNAc-terminated glycans are 
present in antigens of bacteria and protozoa [20, 21]. 
Neoplasia can disrupt the intact mucosal barrier to en-
teric microbiota. The elevated level of some anti-glycan 
IgGs in sera of patients with gastrointestinal cancer may 
reflect the adaptive immune response to microorganisms 
and may be indirectly associated with better or worse 
survival via beneficial or detrimental interrelation between 
microorganisms and tumor.
The X2 and PF glycolipids have been isolated from 
human erythrocytes and X2 has been found in various 
human tissues including carcinomas. The above antigens 
are extremely minor components; therefore, they can-
not be detected on the cell surface [22–25]. It seems 
to be improbable that the antibo dies described could 
be autoreactive, binding the minor glycolipids of cellular 
membranes. Moreover, the presumably “auto” antibo-
dies were found to bind short fragments of larger glycans 
whereas recognition of the same fragment in the context 
of the whole natural chain was completely abolished [16].
Thus, the anti-GalNAc IgGs isolated from the serum 
of gastric cancer survivors demonstrated the cross-
reactivity to the X2di glycan mainly. The isolated anti-X2di 
and -PFdi IgGs demonstrated monoreactivity to the corre-
sponding key glycan-PAA used for isolation of antibodies. 
The findings provide additional information for elucida-
tion of the immunopathological role of cross-reactive 
antibodies to GalNAc-terminated glycans in cancer and 
enhancement of the prognostic potential in the combined 
determination of antibody markers.
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